This is the intermediate of abiraterone acetate. Abiraterone acetate is a precursor drug of abiraterone and a drug targeting androgen receptor signal pathway. Abiraterone acetate is a highly selective and powerful inhibitor of cytochrome oxidase CYP17. Its inhibitory effect is irreversible, which is 10 ~ 30 times stronger than the non selective inhibitor ketoconazole.
Clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (PSA) in patients with prostate cancer, help to reduce the tumor, and prolong the life of patients with advanced prostate cancer for several years.
1. Abiraterone acetate is a CYP17 inhibitor used in combination with prednisone to treat prostate cancer patients who have received docetaxel chemotherapy metastasis.
2. Abiraterone acetate is a precursor drug, which can be transformed into abiraterone after entering the body. The latter is an androgen biosynthesis inhibitor, which exerts its curative effect by inhibiting the activity of CYP17 enzyme and then inhibiting androgen biosynthesis.